Evidence map›Paper›PMID 35820081›Full record

ArticleJCO global oncology2022

Nephroblastoma Treatment and Outcomes in a Low-Income Setting.

Cyprien Shyirambere, Chandler Villaverde, Cam Nguyen, Deogratias Ruhangaza, Aline Umwizerwa, Oscar Nsanzimana, Louis Mujyuwisha, Esperance Iradukunda, Lawrence N Shulman, Leslie Lehmann

Registry-linked trialAbstract read
In one paragraph

Article in JCO global oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06928909 (Evaluating the Feasibility of an Intensity-Adapted Pediatric Acute Myeloid Leukemia Treatment Guideline in Malawi), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06928909 recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluating the Feasibility of an Intensity-Adapted Pediatric Acute Myeloid Leukemia Treatment Guideline in Malawi

TypeobservationalSponsorBaylor College of MedicineRan2025 to 2030Enrolled30ConditionsAcute Myeloid LeukaemiaArmsIntensity-adapted pediatric acute myeloid treatment guidelines
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cyprien ShyiramberePartners in Health/Inshuti Mu Buzima, Kigali, Rwanda.ORCID 0000-0002-3203-3873
Chandler VillaverdeUniversity of Washington, Seattle, WA.
Cam NguyenUniversity of Colorado Cancer Center, Aurora, CO.
Deogratias RuhangazaMinistry of Health, Kigali, Rwanda.
Aline UmwizerwaPartners in Health/Inshuti Mu Buzima, Kigali, Rwanda.ORCID 0000-0002-1620-3297
Oscar NsanzimanaPartners in Health/Inshuti Mu Buzima, Kigali, Rwanda.
Louis MujyuwishaPartners in Health/Inshuti Mu Buzima, Kigali, Rwanda.
Esperance IradukundaMinistry of Health, Kigali, Rwanda.
Lawrence N ShulmanAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-8661-473X
Leslie LehmannChildren's Hospital Boston, Boston, MA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNephroblastoma is a highly curable pediatric cancer that requires multidisciplinary care. Few reports have assessed long-term treatment outcomes in low-resource settings using a task-shifting model of care. We report outcomes of a large cohort and factors associated with survival.

methodsWe performed a retrospective chart review of all patients with nephroblastoma presenting to the Butaro Cancer Center of Excellence in Rwanda between July 2012 and June 2018.

resultsIn total, 136 patients were identified and treated according to International Society of Pediatric Oncology guidelines for low-income settings. Median age at diagnosis was 39.7 months (interquartile range, 25.3-61.8 months); 56.6% were female. Sixty-one (44.9%) patients presented with stage I-III disease, 35 (25.7%) with stage IV disease, and 6 (4.4%) with stage V disease; the remainder were unstaged (n = 34; 25.0%). Most patients completed surgery (n = 97; 71.3%) and postoperative chemotherapy (n = 82; 60.2%); 17 patients received radiotherapy. With a median follow-up time of 18.1 months, 44.9% of patients were alive, 41.9% had died, 8.8% were lost to follow-up, and 4.4% were referred for palliative care or declined further care at the end of the study. Three-year overall survival was 57.5% (95% CI, 48.1 to 65.8) for the entire cohort, and 80.1% (95% CI, 66.8 to 88.5) and 44.0% (95% CI, 26.8 to 60.0) for stages I-III and IV-V, respectively.

conclusionWe demonstrate that patients with nephroblastoma can be successfully treated in a low-resource setting. Survival remains lower than in high-income countries, in part due to early deaths, contributing to approximately 30% of patients not being medically able to receive surgical intervention. Next steps include the development of strategies that focus on earlier diagnosis, supportive care during the early phases of therapy, and efficient and timely transitions between specialties for multimodal care.

Indexed as

Kidney NeoplasmsWilms TumorChildChild, PreschoolFemaleHumansMalePovertyRetrospective StudiesTreatment Outcome

Identifiers

PMID35820081
PMCPMC9296183

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.